Pinion Immunotherapeutics CEO Dr. Gregory Glenn to Speak at World Vaccine Congress Europe 2026 in Amsterdam
Panel on chronic conditions and off-target effects of vaccines, and a presentation on Pinion’s EBV immunotherapeutic program ROCKVILLE, Md. — Pinion Immunotherapeutics, a clinical-stage biotechnology company developing A
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.